Recent clinical trials with the patritumab deruxtecan (HER3-Dxd; an Ab-drug conjugate (ADC) consisting of an anti-HER3 Ab and topoisomerase I inhibitor payload) have produced impressive results in non-small cell lung cancer (NSCLC) patients with EGFR-TKI resistance40,41. The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.